Sign Up | Log In | What is SocialPicks?

Inspire Pharmaceuticals Inc. (ISPH) Trade Now » Rate ISPH - Discuss ISPH - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

100.0%

Top:

100.0%

Rate ISPH:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ISPH Analysis & Videos »

... View All >

ISPH: Bull or Bear?

Inspire Pharmaceuticals Inc. ISPH

N/A

+33.17%
in 58 days

Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clini...

Continue reading »

By supratrader (+10.80% risk: conservative) 05/10/09

Comment

Bullish on ISPH ... ISPH

62%

+33.17%
in 59 days

nspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinic...

Continue reading »

By Marian Filo (-24.55% risk: aggressive) 05/09/09

Comment

Eyeing Opportunities in Micro-Cap Bio-Pharma Index ISPH

73%

+58.46%
in 216 days

Eyeing Opportunities in Micro-Cap Bio-Pharma Index

<>
The accompanying table profiles the 13 companies mentioned in this article and statistics for all 113 companies [ click here for a link to the entire index ] with market caps between $25M-$150M, which are included in the new ETF Innovators [ETFI] Micro-Cap Bio-Pharma Index as a complement to the ETFI Emerging Bio-Pharma Index of companies with market caps between $150M-$1.5B.

The Micro-Cap Bio-Pharma Index was hit especially hard over the past year, posting a decline over 41% while the Emerg...

Continue reading »

By Mike Havrilla (+1.04% risk: conservative) 12/02/08

Comment

Robust Pipeline at Inspire Pharma ISPH

+8.32%
in 392 days

We believe the positive data for Denufosol bodes well for the company, since the drug candidate can act as a long term value driver for Inspire.

Continue reading »

By Zacks.com (-19.77% risk: moderate) 06/09/08

Comment

Bullish on ISPH ... ISPH

+39.66%
in 27 days
(closed on 06/09/08)

Continue reading »

By Zacks.com (-19.77% risk: moderate) 05/13/08

Comment

... View All >

People Bullish on ISPH

supratrader

Principal

N/A

about 1 mo ago

Marian Filo

Principal

62%

about 1 mo ago

Mike Havrilla

Principal

73%

7 mos ago

rmarty

Sr. Analyst

46%

10 mos ago

Zacks.com

Tracked Blogger

28%

about 1 year ago

People Bearish on ISPH

... View All >

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+43.39%	272
2	Gerald Greene	18.14	+59.31%	139
3	stockmarketfunding.com	17.66	+22.00%	34
4	akiralegrand	13.47	+15.91%	48
5	anup2104	12.13	+37.83%	12

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
V	Visa Inc
AMZN	Amazoncom Inc
JNJ	Johnson & Johnson
AMD	Advanced Micro Devices Inc
CSCO	Cisco Systems Inc
ETFC	E*Trade Financial Corp

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

PLX		BioMedReports: FDA Calendar Updates by Mike Havrilla
HX		Halifax Confident About Pushing Towards Profitibility by The GeoTeam
APPY		Extreme FDA Medical Device Trades: 7 Stocks Under $5 by Mike Havrilla
ARYX		Extreme FDA Calendar Trades: 18 Stocks Under $5 by Mike Havrilla
DGX		Quest Diagnostics Inc. by Marian Filo

... more »

StreetInsider.com on ISPH

Form 4 YERXA BENJAMIN R For: Jul 01

Form 4 YERXA BENJAMIN R For: Jun 15

Inspire Announces Presentations at European Cystic Fibrosis Society Annual Meeting

Form 4 INSPIRE PHARMACEUTICALS For: Jun 05 Filed by: LEFF JONATHAN S

Form 4 HOLMER ALAN F For: Jun 05

Discussion Wall

+ Add

Be the first to start a discussion and earn 2 points.

... more »

More Resources

About Inspire Pharmaceuticals Inc. - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.